Published online Apr 28, 2017. doi: 10.4254/wjh.v9.i12.567
Peer-review started: December 6, 2016
First decision: January 16, 2017
Revised: February 21, 2017
Accepted: March 12, 2017
Article in press: March 13, 2017
Published online: April 28, 2017
Severe alcoholic hepatitis is implicated as a costly, worldwide public health issue with high morbidity and mortality. The one-month survival for severe alcoholic hepatitis is low with mortality rates high as 30%-50%. Abstinence from alcohol is the recommended first-line treatment. Although corticosteroids remain as the current evidence based option for selected patients with discriminant function > 32, improvement of short-term survival rate may be the only benefit. Identification of individuals with risk factors for the development of severe alcoholic hepatitis may provide insight to the diverse clinical spectrum and prognosis of the disease. The understanding of the complex pathophysiologic processes of alcoholic hepatitis is the key to elucidating new therapeutic treatments. Newer research describes the use of gut microbiota modification, immune modulation, stimulation of liver regeneration, caspase inhibitors, farnesoid X receptors, and the extracorporeal liver assist device to aid in hepatocellular recovery. Liver transplantation can be considered as the last medical option for patients failing conventional medical interventions. Although the preliminary data is promising in patients with low risk of recividism, controversy remains due to organ scarcity. This review article comprehensively summarizes the epidemiology, pathophysiology, risk factors, and prognostic indicators of severe alcoholic hepatitis with a focus on the current and emerging therapeutics.
Core tip: Current research of alcoholic hepatitis pathophysiology via translational research has provided insight to novel therapeutic options. Recovery from severe alcoholic hepatitis with assistance of gut microbiota modification, immune modulators, stimulation of liver regeneration, caspase inhibitors, farnesoid X receptors, and extracorporeal liver assist device may be promising.